Oxidized low-density lipoprotein (oxLDL) epitope

Class

Human recombinant monoclonal antibody targeting oxidized LDL

Pathway

Binds a specific oxLDL epitope, neutralizing pro-atherogenic oxidized-LDL signaling implicated in endothelial dysfunction and plaque formation

Notes

original target text: Oxidized low-density lipoprotein (oxLDL) epitope (malondialdehyde-modified LDL, MDA-LDL)

Low-density lipoprotein (LDL) particles that undergo oxidative modification in the arterial wall generate a family of altered structures, including malondialdehyde-modified LDL (MDA-LDL), that are no longer recognized by the normal LDL receptor. Instead, these oxidized particles are taken up by scavenger receptors on macrophages and can directly injure the endothelium, the single-cell lining of blood vessels. This process is a central early step in atherosclerosis: oxidized LDL promotes endothelial dysfunction, recruits circulating monocytes into the vessel wall, and drives the transformation of macrophages into lipid-laden foam cells that form the core of atherosclerotic plaque. A monoclonal antibody directed against a specific oxLDL epitope is designed to bind and neutralize these oxidized particles before they can engage scavenger receptors or damage endothelial cells, in principle interrupting the sequence of events that leads to plaque initiation and growth. This approach targets the vascular biology of atherosclerosis directly, rather than acting solely by lowering circulating LDL cholesterol levels as conventional lipid-lowering therapies do. Because oxidative modification of LDL is implicated across the spectrum of atherosclerotic cardiovascular disease, including coronary artery disease and peripheral vascular disease, this mechanism is broadly relevant wherever plaque formation and vascular inflammation are disease drivers.